---
layout: post
title: "Sameness Evaluations in an Abbreviated New Drug Application-Active Ingredients; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-24432
original_published: 2022-11-09 00:00:00 +0000
significance: 8.00
---

# Sameness Evaluations in an Abbreviated New Drug Application-Active Ingredients; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 09, 2022 00:00 UTC
**Document Number:** 2022-24432

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sameness Evaluations in an ANDA--Active Ingredients." This guidance is intended to assist applicants preparing an abbreviated new drug application (ANDA) by providing recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug (RLD).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/09/2022-24432/sameness-evaluations-in-an-abbreviated-new-drug-application-active-ingredients-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-24432

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
